• Gastric Cancer Assembloids and Drug Response

  2026-10-09

  The 2025 reference study introduces patient-derived gastric cancer assembloids that combine tumor organoids with matched stromal cell subpopulations. Its findings show that stromal context changes gene expression and drug sensitivity, supporting more physiologically relevant studies of resistance and personalized treatment response.

• Matrine, YTHDF1, and Thymoma Stemness

  2026-10-08

  A 2026 study links Matrine exposure with reduced stemness-associated behavior and increased apoptosis in EL-4-B5 thymoma cells, identifying YTHDF1 and Wnt/β-catenin signaling as candidate mediators. The work is an informative in vitro mechanism framework, but the absence of direct m6A measurements, animal studies, and clinical validation limits causal and translational conclusions.

• Deferasirox Fe3+ Chelate and Lysosomal Iron Biology

  2026-10-08

  Deferasirox Fe3+ chelate offers a chemically defined lens for interpreting iron-dependent lysosomal stress. This article connects Exjade-related iron chelation research with Ren et al.’s 2025 findings on TCF25, V-ATPase, ferritinophagy, and lysosome-dependent cell death while clearly separating evidence from hypothesis.

• CD38 CAR Binder Structures and Affinity Tuning

  2026-10-07

  Cheng and colleagues combine structural biology, mutational analysis, enzymatic testing, and CAR-T functional studies to explain how two CD38 binders engage the antigen differently. The findings show that affinity, epitope geometry, catalytic inhibition, and fratricide are linked but separable design variables, offering a mechanistic framework for interpreting CD38-targeted CAR optimization.

• RESTRICT-seq and Epigenetic Dependencies in SCC

  2026-10-07

  A 2025 bioRxiv preprint presents RESTRICT-seq as a framework for time-gated CRISPR screening and applies it to the study of epigenetic dependencies associated with SCC resistance. The work is conceptually important for separating temporal effects from resistance phenotypes, but its interpretation remains provisional because the supplied record contains no gene-level results, quantitative effect sizes, or peer-reviewed validation.

• Mubritinib–HSA Binding Study: Methods and Findings

  2026-10-06

  The 2023 reference study combines fluorescence spectroscopy, biochemical analysis, and molecular docking to characterize how mubritinib interacts with human serum albumin. Its findings support moderate-affinity binding at Sudlow site I, measurable local and structural perturbations, and inhibition of albumin esterase-like activity, while also defining important limits on pharmacokinetic interpretation.

• Nanoparticle Uptake by Human Corneal Cells

  2026-10-06

  Azadi and David examined how nanoparticle size and surface chemistry shape uptake by human corneal epithelial cells in a mucosa-informed in vitro model. Their results connect physicochemical properties with probable endocytic routes, while also showing why pathway assignments and cross-study applications require careful controls and cautious interpretation.

• Quercetin in LPS-Induced Depression: Key Findings

  2026-10-05

  A 2026 pre-proof study reports that quercetin reduced depressive-like behaviors, cognitive deficits, and hippocampal inflammatory signals in an LPS-induced mouse model. Its central contribution is linking these effects to suppression of NLRP3 inflammasome-associated neuroinflammation, while leaving clinical efficacy and broader molecular mechanisms unresolved.

• DRB and Cell-Fate Research: Evidence and Limits

  2026-10-05

  A source-grounded overview of DRB as a transcriptional elongation probe, its conceptual relevance to YTHDF1-driven spermatogonial stem-cell transdifferentiation, and the limitations separating established findings from future research questions.

• Data-Driven Design of Small-Molecule Libraries

  2026-10-04

  Moret et al. present a data-driven framework for comparing and designing focused small-molecule libraries using target coverage, binding selectivity, cellular phenotypes, chemical structure, clinical status, and user preferences. Their LSP-OptimalKinase and LSP-MoA collections show how computational selection can improve coverage while limiting redundancy, although the framework does not by itself establish biological or therapeutic efficacy.

• Sulforaphane, Oxidative Stress, and NLRP3 in Colitis

  2026-10-03

  A 2024 study links Sulforaphane treatment with reduced oxidative stress, lower NLRP3 inflammasome activity, and improved colitis-associated pathology in mice. Its integrated animal and cell-model evidence supports Sulforaphane as a mechanistic probe for redox–inflammation research, while remaining insufficient to establish clinical efficacy or direct NLRP3 inhibition in humans.

• Nanoparticle Uptake in Human Corneal Cells

  2026-10-02

  Azadi and David’s 2024 study links PLGA nanoparticle size and surface chemistry with uptake behavior in human corneal epithelial cells. Its mucosa-integrated in vitro model shows that energy-dependent endocytosis dominates, with macropinocytosis and caveolae-mediated uptake contributing most strongly and providing a practical framework for ocular nanomedicine design.

• Mifepristone (RU486): Applied Research Workflows

  2026-10-01

  Turn progesterone-receptor antagonism into reproducible cancer, reproductive-biology, and mechanism-focused assays with practical dosing, controls, and troubleshooting. This guide pairs Mifepristone use cases with a compartment-aware lesson from a neuropharmacology reference study without overstating cross-domain evidence.

• PEG 400, Quercetin, and BCRP-Linked Exposure

  2026-10-01

  A recent International Journal of Pharmaceutics study shows that PEG 400 substantially increases oral quercetin and quercetin-3-O-β-D-glucuronide exposure while improving anti-inflammatory activity in rats. By combining pharmacokinetics, spatial mass spectrometry imaging, metabolic models, transporter assays, and an inflammation model, the work frames solubility, UGT1A9 metabolism, and BCRP/MRP2 efflux as interconnected determinants of flavonoid disposition.

• Simvastatin (Zocor): From Lipids to Cell Stress

  2026-09-30

  A translational perspective on Simvastatin (Zocor) that connects HMG-CoA reductase inhibition with lipid metabolism, hepatic cancer phenotypes, and stress-response biology while defining practical validation strategies and the limits of cross-domain interpretation.

8077 records 1/539 page Next 12345 下5页 Last page